@article{oai:niigata-u.repo.nii.ac.jp:00017290,
 author = {鈴木, 訓充},
 issue = {7},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Jul},
 note = {Ideal somatic gene therapy for genetic diseases is to replace the abnormal gene with a normal gene and to normalize the abnormal cells. Up to now, repair of an abnormal gene can be performed only by homologous recombination between the abnormal gene and the gene used for correction. Our study was designed to assess whether homologous recombination occurs in hematopoietic cells and to see if it is possible to apply homologous recombination. Murine hematopoietic cell line, FDC-P2, which becameIL-3 independent by being transfected with p210bcr-abl, was used for the target cell. In order to perform such gene replacement, we constructed the vector for homologous recombination. The plasmid was made by inserting Neo-gene in the region of the bcr-abl, thymidine kinase gene outside of bcr-abl, and placing bcr-abl in antidromic way for restricting the homologous recombination to bcr-abl area. Transfection was performed by electroporation and selection was done by culture adding G418 and gancyclovir. One clone was established and was confirmed to be replaced by the vector constructed for homologous recombination by the detection of no transcriotion of thymidine kinase and bcr-abl, but positive trsnscription of Neo gene in RT-PCR analysis, and by the expected changes in the size of the bands in Southern blot analysis. Reaquisition of IL-3 dependency was demonstrated in the cells which autonomously proliferate in the IL-3 free condition. These findings suggest the possibility of homologous recombination as the gene replacement therapy in hematological diseases including leukemias.},
 pages = {460--470},
 title = {相同組み換えによる異常遺伝子を標的とした遺伝子破壊の試み : 造血器腫瘍への遺伝子治療の可能性},
 volume = {111},
 year = {1997}
}